Psoriasis: From Pathogenesis to Pharmacological and Nano-Technological-Based Therapeutics

Vista senzilla d'ítem
dc.contributor.authorGironés Petit, Robert
dc.contributor.authorCano Fernández, Amanda
dc.contributor.authorOrtiz Rodrigo, Alba
dc.contributor.authorEspina García, Marta
dc.contributor.authorPrat Aixelà, Josefa
dc.contributor.authorMuñoz Juncosa, Montserrat
dc.contributor.authorSeverino, Patrícia
dc.contributor.authorSouto, Eliana B.
dc.contributor.authorGarcía López, María Luisa
dc.contributor.authorPujol Cubells, Montserrat
dc.contributor.authorSánchez-López, E. (Elena)
dc.date.accessioned2021-05-20T09:58:42Z
dc.date.available2021-05-20T09:58:42Z
dc.date.issued2021-05-07
dc.date.updated2021-05-20T09:58:42Z
dc.description.abstractResearch in the pathogenesis of inflammatory skin diseases, such as skin dermatitis and psoriasis, has experienced some relevant breakthroughs in recent years. The understanding of age-related factors, gender, and genetic predisposition of these multifactorial diseases has been instrumental for the development of new pharmacological and technological treatment approaches. In this review, we discuss the molecular mechanisms behind the pathological features of psoriasis, also addressing the currently available treatments and novel therapies that are under clinical trials. Innovative therapies developed over the last 10 years have been researched. In this area, advantages of nanotechnological approaches to provide an effective drug concentration in the disease site are highlighted, together with microneedles as innovative candidates for drug delivery systems in psoriasis and other inflammatory chronic skin diseases. View Full-Text Keywords: skin inflammatory diseases; psoriasis; psoriasis versus atopic dermatitis; biodegradable nanoparticles; microneedles; clinical trials
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec712199
dc.identifier.issn1661-6596
dc.identifier.pmid34067151
dc.identifier.urihttps://hdl.handle.net/2445/177455
dc.language.isoeng
dc.publisherMDPI
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/ijms22094983
dc.relation.ispartofInternational Journal of Molecular Sciences, 2021, vol. 22, num. 9, p. 4983
dc.relation.urihttps://doi.org/10.3390/ijms22094983
dc.rightscc-by (c) Gironés Petit, Robert et al., 2021
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourceArticles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)
dc.subject.classificationMalalties de la pell
dc.subject.classificationPsoriasi
dc.subject.classificationDermatitis
dc.subject.otherSkin diseases
dc.subject.otherPsoriasis
dc.subject.otherDermatitis
dc.titlePsoriasis: From Pathogenesis to Pharmacological and Nano-Technological-Based Therapeutics
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Miniatura
Nom:
712199.pdf
Mida:
1.77 MB
Format:
Adobe Portable Document Format
Descarregar

Col·leccions

Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)